Aquestive Therapeutics Ownership | Who Owns Aquestive Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Aquestive Therapeutics Ownership Summary


Aquestive Therapeutics is owned by 51.35% institutional investors, 5.01% insiders, and 43.64% retail investors. Bratton capital management is the largest institutional shareholder, holding 13.33% of AQST shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.64% of its assets in Aquestive Therapeutics shares.

AQST Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAquestive Therapeutics51.35%5.01%43.64%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustrySpecialty & Generic Drug Manufacturers Stocks34.90%10.53%54.58%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bratton capital management9.81M13.33%$25.51M
Vr adviser5.56M7.55%$14.44M
Blackrock5.45M7.41%$14.18M
Vanguard group4.23M5.74%$10.99M
Franklin resources2.85M3.88%$7.42M
Geode capital management1.58M2.14%$4.10M
Blue owl capital lp1.14M1.55%$2.96M
State street984.06K1.34%$2.56M
Janney montgomery scott880.49K1.20%$2.29M
Nuveen asset management785.02K1.07%$2.04M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Bratton capital management9.81M100.00%$25.51M
Vr adviser5.56M0.92%$14.44M
Blue owl capital lp1.14M0.82%$2.96M
Latash investments243.13K0.51%$632.15K
Essex investment management705.18K0.34%$1.83M
Diametric capital, lp242.71K0.34%$631.05K
Dafna capital management530.00K0.33%$1.38M
Bracebridge capital428.57K0.20%$1.11M
Cahill wealth management118.56K0.18%$308.26K
Legato capital management242.37K0.08%$630.16K

Top Buyers

HolderShares% AssetsChange
Blackrock5.45M0.00%4.11M
Geode capital management1.58M0.00%1.04M
Vanguard group4.23M0.00%985.10K
State street984.06K0.00%802.42K
Nuveen asset management785.02K0.00%785.02K

Top Sellers

HolderShares% AssetsChange
Laurion capital management lp---1.55M
Monashee investment management---1.00M
Renaissance496.20K0.00%-879.60K
Invesco89.04K--808.47K
Ghost tree capital---702.94K

New Positions

HolderShares% AssetsChangeValue
Nuveen asset management785.02K0.00%785.02K$2.04M
Deerfield management company, l.p. (series c)146.16K0.01%146.16K$380.00K
Rhumbline advisers97.84K0.00%97.84K$254.37K
Alliancebernstein41.28K-41.28K$107.33K
Corebridge financial39.95K0.00%39.95K$104.28K

Sold Out

HolderChange
Highmark wealth management-50.00
Headlands-269.00
Creative financial designs inc /adv-700.00
Federated hermes-1.40K
Macquarie group-3.71K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202412223.23%46,774,77210.17%511.54%7931.67%23-
Jun 30, 202499-3.88%42,456,8902.32%571.26%60-18.92%2364.29%
Mar 31, 202410368.85%41,494,84874.43%675.01%74131.25%147.69%
Dec 31, 20236117.31%23,788,7933.91%362.31%3268.42%13-
Sep 30, 202352-8.77%22,893,94620.01%393.39%19-54.76%13550.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.40M2.64%-
iShares Russell 2000 ETF1.92M2.11%-4.31K
Franklin Biotechnology Discv A(acc)USD1.42M1.55%-355.50K
Vanguard Institutional Extnd Mkt Idx Tr1.12M1.23%-3.98K
Franklin Biotechnology Discovery A993.80K1.09%-
Fidelity Small Cap Index760.52K0.84%-18.73K
Invesco Dorsey Wright SmallCap Momt ETF748.44K0.82%-
Nuveen Equity Index R6649.35K0.71%-
iShares Russell 2000 Value ETF512.89K0.56%-
State St Russell Sm/Mid Cp® Indx NL Cl C441.98K0.48%-15.30K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 26, 2024Jung Cassie Chief Operating OfficerSell$214.06
Mar 15, 2024Schobel Alexander Mark Chief Innovation/Tech OfficerSell$300.00K
Mar 08, 2024Schobel Alexander Mark Chief Innovation/Tech OfficerSell$129.69K
Jun 14, 2022Boyd Peter E. SVP-Bus. Process & Info. Tech.Buy$4.05K
Jun 08, 2022Barber Daniel Chief Executive OfficerBuy$88.07K

Insider Transactions Trends


DateBuySell
2024 Q4-1
2024 Q3--
2024 Q2--
2024 Q1-2
2023 Q3--

AQST Ownership FAQ


Who Owns Aquestive Therapeutics?

Aquestive Therapeutics shareholders are primarily institutional investors at 51.35%, followed by 5.01% insiders and 43.64% retail investors. The average institutional ownership in Aquestive Therapeutics's industry, Specialty & Generic Drug Manufacturers Stocks, is 34.90%, which Aquestive Therapeutics exceeds.

Who owns the most shares of Aquestive Therapeutics?

Aquestive Therapeutics’s largest shareholders are Bratton capital management (9.81M shares, 13.33%), Vr adviser (5.56M shares, 7.55%), and Blackrock (5.45M shares, 7.41%). Together, they hold 28.28% of Aquestive Therapeutics’s total shares outstanding.

Does Blackrock own Aquestive Therapeutics?

Yes, BlackRock owns 7.41% of Aquestive Therapeutics, totaling 5.45M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 14.18M$. In the last quarter, BlackRock increased its holdings by 4.11M shares, a 305.59% change.

Who is Aquestive Therapeutics’s biggest shareholder by percentage of total assets invested?

Bratton capital management is Aquestive Therapeutics’s biggest shareholder by percentage of total assets invested, with 100.00% of its assets in 9.81M Aquestive Therapeutics shares, valued at 25.51M$.

Who is the top mutual fund holder of Aquestive Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Aquestive Therapeutics shares, with 2.64% of its total shares outstanding invested in 2.4M Aquestive Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools